Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com
過去 90 日內有 30 個訊號。
此公司進入各市場的次序 — 由最舊至最新
Harbour BioMed任命Patel博士為顧問
Harbour BioMed任命Patel博士為顧問
註冊以查看完整訊號動態
Harbour BioMed 的國際擴張與競爭對手的比較
Harbour BioMed你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Harbour BioMed你 | 3 | 0 | +36% | 26 | 50 |
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
和鉑醫藥任命Adam Zong博士為總裁,負責加強產品管線、推進組合策略及領導合作夥伴關係。Zong擁有超過20年生物製藥經驗,曾任職默克、百時美施貴寶、輝瑞及恒瑞醫藥。
和鉑醫藥的HBM9378（針對TSLP的新型抗體）I期試驗顯示良好安全性和延長半衰期，支持進一步開發用於嚴重免疫疾病。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Harbour BioMed 業務、市場及增長訊號的快速解答。
